EGFR and non-small cell lung carcinoma: Eighteen studies [9–11, 17–19, 21, 22, 31, 32, 34, 35, 40–42, 46, 49, 51] investigated outcomes (response rate or PFS) of EGFR-TKIs treatment in stage IIIb-IV unresectable NSCLC comparing KRAS mutant tumors with KRAS wild-type tumors.